Commonwealth Equity Services
KPTI icon

Commonwealth Equity Services’s Karyopharm Therapeutics KPTI Stock Holding History

Commonwealth Equity Services’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,486
Closed -$15K – 4229
2024
Q4 		$15K Buy
1,486
+6
+0.4% +$73 ﹤0.01% 4053
2024
Q3 		$18K Sell
1,480
-200
-12% -$2.48K ﹤0.01% 4004
2024
Q2 		$22K Sell
1,680
-14
-0.8% -$232 ﹤0.01% 3963
2024
Q1 		$38K Buy
+1,694
New +$29.7K ﹤0.01% 3922
2022
Q4 		– Sell
-678
Closed -$55K – 3752
2022
Q3 		$55K Sell
678
-188
-22% -$14K ﹤0.01% 3474
2022
Q2 		$58K Sell
866
-7
-0.8% -$642 ﹤0.01% 3464
2022
Q1 		$96K Sell
873
-40
-4% -$4.99K ﹤0.01% 3501
2021
Q4 		$88K Buy
913
+64
+8% +$6.38K ﹤0.01% 3482
2021
Q3 		$74K Buy
+849
New +$88.1K ﹤0.01% 3457
2021
Q1 		– Sell
-676
Closed -$156K – 3435
2020
Q4 		$156K Buy
+676
New +$157K ﹤0.01% 2982
2020
Q1 		– Sell
-670
Closed -$192K – 2898
2019
Q4 		$192K Sell
670
-192
-22% -$41.7K ﹤0.01% 2629
2019
Q3 		$124K Buy
+862
New +$117K ﹤0.01% 2642

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Commonwealth Equity Services's KPTI Position: Q1 2025 in Review

Commonwealth Equity Services sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 1,486 shares — an estimated $15K sold.

Commonwealth Equity Services first reported a position in KPTI in Q3 2019 and held it in 12 quarters. The position peaked at $192K in Q4 2019. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

  • Commonwealth Equity Services reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Commonwealth Equity Services sold 1,486 Karyopharm Therapeutics shares in Q1 2025, an estimated $15K.
  • Commonwealth Equity Services first reported a position in Karyopharm Therapeutics in Q3 2019 and held it in 12 quarters.
  • Commonwealth Equity Services's Karyopharm Therapeutics position peaked at $192K in Q4 2019.
  • 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Commonwealth Equity Services's 13F filing for Q1 2025, filed 9 May 2025.